Impact of VKORC1 gene polymorphism on interindividual and interethnic warfarin dosage requirement- A systematic review and meta analysis

Thrombosis Research

Volumn 125, Issue 4, 2010, Pages

  Yang, Limei ^a   Ge, Weihong ^a   Yu, Feng ^b   Zhu, Huaijun ^a  

^a THE AFFILIATED DRUM TOWER HOSPITAL OF NANJING UNIVERSITY MEDICAL SCHOOL   (China)

^b CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Gene polymorphism; Meta analysis; Systematic review; VKORC1; Warfarin

Indexed keywords

OXIDOREDUCTASE; UNCLASSIFIED DRUG; VITAMIN K EPOXIDE REDUCTASE COMPLEX SUBUNIT 1; WARFARIN;

ARTICLE; ASIAN; CAUCASIAN; DNA POLYMORPHISM; DRUG DOSE REGIMEN; ETHNIC DIFFERENCE; GENE FREQUENCY; HETEROZYGOTE; HUMAN; NEGRO; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMATIC REVIEW;

ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; CARBON-CARBON LIGASES; CLINICAL PROTOCOLS; CONTINENTAL POPULATION GROUPS; ETHNIC GROUPS; HUMANS; POLYMORPHISM, GENETIC; PROTEINS; WARFARIN;

EID: 77949567067     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2009.10.017     Document Type: Article

References (40)

1. Aithal G.P., Day C.P., Kesteven P.J., and Daly A.K. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 353 (1998) 717-719
2. D'Andrea G., D'Ambrosio R.L., Di Perna P., Chetta M., Santacroce R., Brancaccio V., et al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 105 (2005) 645-649
3. Miao L., Yang J., Huang C., and Shen Z. Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients. Eur J Clin Pharmacol 63 (2007) 1135-1141
4. Hillman M.A., Wilke R.A., Caldwell M.D., Berg R.L., Glurich I., and Burmester J.K. Relative impact of covariates in prescribing warfarin according to CYP2C9 genotype. Pharmacogenetics 14 (2004) 539-547
5. Momary K.M., Shapiro N.L., Viana M.A., Nutescu E.A., Helgason C.M., and Cavallari L.H. Factors influencing warfarin dose requirements in African-Americans. Pharmacogenomic 8 (2007) 1535-1544
6. Khan T., Wynne H., Wood P., Torrance A., Hankey C., Avery P., et al. Dietary vitamin K influences intra-individual variability in anticoagulant response to warfarin. Br J Haematol 124 (2004) 348-354
7. Greenblatt D.J., and von Moltke L.L. Interaction of warfarin with drugs, natural substances, and foods. J Clin Pharmacol 45 (2005) 127-132
8. Rost S., Fregin A., Ivaskevicius V., Conzelmann E., Hörtnagel K., Pelz H.J., et al. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 427 (2004) 537-541
9. Li T., Chang C.Y., Jin D.Y., Lin P.J., Khvorova A., and Stafford D.W. Identification of the gene for vitamin K epoxide reductase. Nature 427 (2004) 541-544
10. Yuan H.Y., Chen J.J., Lee M.T., Wung J.C., Chen Y.F., Charng M.J., et al. A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. Hum Mol Genet 14 (2005) 1745-1751
11. Sconce E.A., Khan T.I., Wynne H.A., Avery P., Monkhouse L., King B.P., et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 106 (2005) 2329-2333
12. Li T., Lange L.A., Li X., Susswein L., Bryant B., Malone R., et al. Polymorphisms in the VKORC1 gene are strongly associated with warfarin dosage requirements in patients receiving anticoagulation. J Med Genet 43 (2006) 740-744
13. Perini J.A., Struchiner C.J., Silva-Assunção E., Santana I.S., Rangel F., Ojopi E.B., et al. Pharmacogenetics of Warfarin: Development of a Dosing Algorithm for Brazilian Patients. Clin Pharmacol Ther 84 (2008) 722-728
14. Aquilante C.L., Langaee T.Y., Lopez L.M., Yarandi H.N., Tromberg J.S., Mohuczy D., et al. Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements. Clin Pharmacol Ther 79 (2006) 291-302
15. Zhu Y., Shennan M., Reynolds K.K., Johnson N.A., Herrnberger M.R., Valdes Jr. R., et al. Estimation of Warfarin Maintenance Dose Based on VKORC1 (- 1639 G > A) and CYP2C9 Genotypes. Clin Chem 53 (2007) 1199-1205
16. Sanderson S., Emery J., and Higgins J. CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: A HuGEnet™ systematic review and meta-analysis. Genet Med 7 (2005) 97-104
17. Lindh J.D., Holm L., Andersson M.L., and Rane A. Influence of CYP2C9 genotype on warfarin dose requirements-a systematic review and meta-analysis. Eur J Clin Pharmacol 65 (2009) 365-375 [Electronic publication 2008 Nov 25]
18. Carlquist J.F., Horne B.D., Muhlestein J.B., Lappé D.L., Whiting B.M., Kolek M.J., et al. Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study. J Thromb Thrombolysis 22 (2006) 191-197
19. Borgiani P., Ciccacci C., Forte V., Romano S., Federici G., and Novelli G. Allelic variants in the CYP2C9 and VKORC1 loci and interindividual variability in the anticoagulant dose effect of warfarin in Italians. Pharmacogenomics 8 (2007) 1545-1550
20. Jiang N.X., Song J., and Xu B. Vitamin K epoxide reductase complex 1 gene polymorphism and warfarin dose requirement in Chinese patients. Zhonghua Xin Xue Guan Bing Za Zhi 35 (2007) 652-654 [Article in Chinese]
21. Kimura R., Miyashita K., Kokubo Y., Akaiwa Y., Otsubo R., Nagatsuka K., et al. Genotypes of vitamin K epoxide reductase, γ-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients. Thromb Res 120 (2007) 181-186
22. Nakai K., Tsuboi J., Okabayashi H., Fukuhiro Y., Oka T., Habano W., et al. Ethnic differences in the VKORC1 gene polymorphism and an association with warfarin dosage requirements in cardiovascular surgery patients. Pharmacogenomics 8 (2007) 713-719
23. Schelleman H., Chen Z., Kealey C., Whitehead A.S., Christie J., Price M., et al. Warfarin Response and Vitamin K Epoxide Reductase Complex 1 in African Americans and Caucasians. Clin Pharmacol Ther 81 (2007) 742-747
24. Zhang W.P., Chen H., Luo J.W., and Wu X.Y. Influence of VKORC1-1639G > A and CYP2C9 1061A/C polymorphisms on warfarin dose. J Med Mol Biol 4 (2007) 396-400 [Article in Chinese]
25. Haug K.B., Sharikabad M.N., Kringen M.K., Narum S., Sjaatil S.T., Johansen P.W., et al. Warfarin dose and INR related to genotypes of CYP2C9 and VKORC1 in patients with myocardial infarction. Thromb J 6 (2008) 7
26. Obayashi K., Nakamura K., Kawana J., Ogata H., Hanada K., Kurabayashi M., et al. VKORC1 gene variations are the major contributors of variation in warfarin dose in Japanese patients. Clin Pharmacol Ther 80 (2006) 169-178
27. Oner Ozgon G., Langaee T.Y., Feng H., Buyru N., Ulutin T., Hatemi A.C., et al. VKORC1 and CYP2C9 polymorphisms are associated with warfarin dose requirements in Turkish patients. Eur J Clin Pharmacol 64 (2008) 889-894
28. Wadelius M., Chen L.Y., Lindh J.D., Eriksson N., Ghori M.J., Bumpstead S., et al. The largest prospective warfarin-treated cohort supports genetic forecasting. Blood 113 (2009) 784-792 [Electronic publication 2008 Jun 23]
29. Yoshizawa M., Hayashi H., Tashiro Y., Sakawa S., Moriwaki H., Akimoto T., et al. Effect of VKORC1 - 1639 G A polymorphism, body weight, age, and serum albumin alterations on warfarin response in Japanese patients. Thromb Res 124 2 (2009) 161-166 [Electronic publication, 2009 Jan 9]
30. El Rouby S., Mestres C.A., LaDuca F.M., and Zucker M.L. Racial and ethnic differences in warfarin response. J Heart Valve Dis 13 (2004) 15-21
31. Rieder M.J., Reiner A.P., Gage B.F., Nickerson D.A., Eby C.S., McLeod H.L., et al. Effect of VKORC1 Haplotypes on Transcriptional Regulation and Warfarin Dose. N Engl J Med 352 (2005) 2285-2293
32. Crawford D.C., Ritchie M., and Rieder M.J. Identifying the genotype behind the phenotype a role model found in VKORC1 and its association with warfarin dosing. Pharmacogenomics 8 (2007) 487-496
33. Gage B.F., and Lesko L.J. Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues. J Thromb Thrombolysis 25 (2008) 45-51
34. Hillman M.A., Wilke R.A., Yale S.H., Vidaillet H.J., Caldwell M.D., Glurich I., et al. A prospective, randomized pilot trial of model-based warfarin dose initiation using CYP2C9 genotype and clinical data. Clin Med Res 3 (2005) 137-145
35. Anderson J.L., Horne B.D., Stevens S.M., Grove A.S., Barton S., Nicholas Z.P., et al. Carlquist JF; Couma-Gen Investigators. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation 116 (2007) 2563-2570
36. Sconce E.A., Daly A.K., Khan T.I., Wynne H.A., and Kamali F. APOE genotype makes a small contribution to warfarin dose requirements. Pharmacogenet Genomics 16 (2006) 609-611
37. Kohnke H., Sörlin K., Granath G., and Wadelius M. Warfarin dose related to apolipoprotein E (APOE) genotype. Eur J Clin Pharmacol 61 (2005) 381-388
38. Kimmel S.E., Christie J., Kealey C., Chen Z., Price M., Thorn C.F., et al. Apolipoprotein E genotype and warfarin dosing among Caucasians and African Americans. Pharmacogenomics J 8 (2008) 53-60
39. Rieder M.J., Reiner A.P., and Rettie A.E. γ-Glutamyl carboxylase (GGCX) tagSNPs have limited utility for predicting warfarin maintenance dose. J Thromb Haemost 5 (2007) 2227-2234
40. Cha P.C., Mushiroda T., Takahashi A., Saito S., Shimomura H., Suzuki T., et al. High-resolution SNP and haplotype maps of the human gamma-glutamyl carboxylase gene (GGCX) and association study between polymorphisms in GGCX and the warfarin maintenance dose requirement of the Japanese population. J Hum Genet 52 (2007) 856-864